← Back to patent-cliff list
Sacibertinib
Tier C — Watch / tradeSacibertinib
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：HER2, EGFR
Indications (approved)：Breast cancer, 食物中毒
Regional status
US
-
EU
-
China
Phase III
2022-01-08
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Sacibertinib?
Approved indications include: Breast cancer, 食物中毒.
When does the Sacibertinib patent expire?
No public expiry year is available for Sacibertinib yet; this page updates once verified.
How do I get a quote for Sacibertinib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-05